IN VITRO ANALYSIS OF NOVEL ANTI-CD20 ANTIBODY GA101 AND RITUXIMAB IN MANTLE CELL LYMPHOMA

被引：0
|
作者：
Heinrich, D. [1 ]
Decheva, K. [1 ]
Weinkauf, M. [1 ]
Hutter, G. [1 ]
Zimmermann, Y. [1 ]
Weiglein, T. [1 ]
Hiddemann, W. [1 ]
Dreyling, M. [1 ]
机构：
[1] Univ Hosp Munich, Dept Med 2, Munich, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0183
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, K.
    Ogura, M.
    Hatake, K.
    Kobayashi, Y.
    Mori, M.
    Uchida, T.
    Suzuki, T.
    Terui, Y.
    Yokoyama, M.
    Hotta, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma
    Alduau, Waleed
    Potluri, Sandeep
    Ivanov, Andrei
    Honeychurch, Jamie
    Beers, Stephen A.
    Chan, Claude
    Shimada, Kazayuki
    Glennie, Martin J.
    Cragg, Mark S.
    Illidge, Tim
    [J]. BLOOD, 2009, 114 (22) : 302 - 303
  • [33] Real Time Analysis of Binding between Rituximab (Anti-CD20 Antibody) and B Lymphoma Cells
    Tan, Liang
    Lin, Peiling
    Chisti, Mohammad M.
    Rehman, Abdul
    Zeng, Xiangqun
    [J]. ANALYTICAL CHEMISTRY, 2013, 85 (18) : 8543 - 8551
  • [34] Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma
    Kazutaka Takagi
    Akira Yoshida
    Hiromichi Iwasaki
    Hitoshi Inoue
    Takanori Ueda
    [J]. Annals of Hematology, 2005, 84 : 548 - 550
  • [35] Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma
    Takagi, K
    Yoshida, A
    Iwasaki, H
    Inoue, H
    Ueda, T
    [J]. ANNALS OF HEMATOLOGY, 2005, 84 (08) : 548 - 550
  • [36] Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
    Bologna, Luca
    Gotti, Elisa
    Manganini, Massimiliano
    Rambaldi, Alessandro
    Intermesoli, Tamara
    Introna, Martino
    Golay, Josee
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (06): : 3762 - 3769
  • [37] GA101, A TYPE II GLYCOENGINEERED ANTIBODY AGAINST CD20 INDUCES SIGNIFICANT IN-VITRO CELL DEATH OF CD20+ AND PREB LYMPHOBLASTIC LYMPHOMA (PBLL)
    Cairo, M.
    Cho, C.
    Ayello, J.
    Levin, M.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 198 - 198
  • [38] Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab
    Woehrer, S
    Streubel, B
    Chott, A
    Hoffmann, M
    Raderer, M
    [J]. LEUKEMIA & LYMPHOMA, 2005, 46 (11) : 1645 - 1649
  • [39] Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
    Heinzerling, L
    Dummer, R
    Kempf, W
    Schmid, MH
    Burg, G
    [J]. ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 374 - 378
  • [40] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
12345